Experimental obesity drug outperforms traditional weight-loss treatments in early research

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by LSEG. New York fitness trainer and gym owner Kenny Santucci discusses concerns about unverified peptide products for muscle building, saying consumers should work with physicians. A new weight-loss drug variation is showing promise in early trials. Research from the Institute for Diabetes and Obesity at Helmholtz Munich in Germany, published in the journal Nature, tested an experimental obesity and diabetes drug called GLP-1-GIP-Lani. The drug combines GLP-1 and GIP — two natural hormones that help regulate appetite and blood sugar, similar to popular weight-loss drugs like Ozempic — with PPAR activity, which may improve insulin sensitivity, inflammation, fat metabolism and liver health. 'NEXT OZEMPIC' AIMS TO DELIVER 30% WEIGHT LOSS WITH FEWER SIDE EFFECTS The team of researchers, led by Professor Timo D. Muller at Helmoltz Munich, called the drug a quint